Article Text

Download PDFPDF
736 Molecular classification and clinical significance in recurrent endometrial adenocarcinomas
  1. Umran Kucukgoz Gulec,
  2. Semra Paydas,
  3. Emine Kilic Bagir,
  4. Eylul Akbal Isik,
  5. Emine Kucukbingoz,
  6. Ghanim Khatib,
  7. Ahmet Baris Guzel and
  8. Mehmet Ali Vardar
  1. Cukurova University Faculty of Medicine, Adana, Turkey


Introduction/Background We need more data on the prognostic importance of molecular classification in cases of recurrent endometrial adenocarcinomas (EAC). This study was aimed to investigate the molecular characteristics of recurrent EAC and relationship with clinical-pathological features.

Methodology Thirty-three recurrent EAC cases followed in our clinic between 2004 and 2000 were evaluated. IHC was performed to detect mismatch repair-deficient (MMRd) and p53 abn. Sanger sequencing method was used for POLE exonuclease domain mutations (POLEmut) and was classified according to Proactive Molecular Risk Classifier for Endometrial cancer (ProMisE) classification. The relationship between prognostic factors and molecular classification was revealed using statistical methods.

Results There were 10 cases in the MMRd group, 9 cases in the p53abn group, and 14 cases in the nonspesific molecular profile (NSMP) group. No POLEmut cases were detected. While there was no difference between the groups in terms of age, co-morbidity, stage, lymph-vascular space invasion (LVSI), lymph node metastasis (LNM), myometrial invasion (MI) (p=0.211; 0.101; 0.639; 0.544; 0.668; 0.835; respectively), there was a statistically significant difference between the histopathological subgroups (p=0.004). In the MMRd group, all 10 cases were grade 3 EAC, while 4 of 9 p53abn cases were serous and 4 cases were mixed type. There was no significant difference between the molecular groups in terms of adjuvant treatment and recurrence sites (p=0.959; 0.492; respectively). While no significant difference was observed between the groups in terms of OS and DFS (p = 0.631; 0.970; respectively), the prognosis of serous cases was worse than the other groups. However, this prognostic difference could not be demonstrated statistically (p = 0.223).

Conclusion In recurrent cases, the prognosis with p53abn cases was worse than the other groups. This group of cases was more likely to have serous and mixed type histopathology. We could not reveal the relationship between clinical-pathological prognostic features and molecular classification.

Disclosures None.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.